At the NRG Oncology Summer Meeting on July 21, 2022, the GOG Foundation, Inc. (GOG-F) Board of Trustees elected Thomas J. Herzog, MD as its next Chairman, succeeding Larry J. Copeland, MD who has served in this role since 2017. Under Dr. Copeland’s leadership, GOG-F has experienced unprecedented growth in its clinical trial program, particularly at GOG-Partners (GOG-P), including including a significantly expanded clinical trial portfolio, further expansion and engagement of its investigator base, development of a clinical trial mentorship program and multiple educational initiatives focused on new agents, clinical trial design and the execution of clinical trials. Dr. Herzog will serve as GOG-F President-elect for one year, assuming the role of President after the July 2023 meeting. organisation.
Dr. Herzog shares: “I am incredibly humbled and deeply honored to have been elected President-Elect of GOG-F. I would like to thank the nomination committee and the foundation board for their support. I am delighted to work with such an exceptional and dedicated team. I especially want to thank Dr. Copeland for his mentorship throughout my career and for his exceptional vision and leadership of our organization during his tenure. He has created a culture that puts the best interests of our patients at the center of the mission to deliver tomorrow’s care today through innovative, practice-changing clinical trials. Operationalizing this mission has required tremendous effort from our leaders, staff and registration sites. As President, I am committed to continuing to foster this exceptional culture by supporting our mission and building on our success, while taking on new challenges for GOG-F and for our patients whom we are so honored to serve.
Dr. Copeland shares, “It was a great time to ‘pass the torch’ and it was important to find the optimal candidate to lead GOG-F.” In accordance with the GOG-F statutes, the governance of the elections was facilitated by a nominating committee following a group-wide request for candidates. Interested individuals were invited to submit an application regarding their intent, qualifications and vision as a potential future leader of GOG-F. Interviews and deliberations led to a candidate who was then presented to the GOG-F Board of Directors, which unanimously elected Dr. Herzog as GOG-F Chair.
Dr. Herzog brings to this position extensive experience in clinical trials and related commercial aspects. A gynecological oncologist and member of the GOG-F Board of Directors, he has served as GOG-F Treasurer for the past 8 years and is currently the Associate Director of the GOG-P Program. He is currently Deputy Director of the University of Cincinnati Cancer Center and Paul & Carolyn Flory Professor in the Department of Obstetrics and Gynecology at the University of Cincinnati. Dr. Herzog has authored/co-authored over 320 peer-reviewed articles and numerous national and international conferences. He sits or has sat on the editorial boards of Gynecological Oncology, Obstetrics and Gynecology International, Hematology Oncology Times, and others. He was editor-in-chief of Female Oncology Review and From gynecological oncology research to practice. Dr. Herzog has served on the board or board of directors of the Society of Gynecologic Oncology, Foundation for Women’s Cancer, American College of Surgeons Board of Governors, American Board of Obstetrics and Gynecology -Gynecologic Oncology Division and the International Gynecologic Cancer Society.
Dr Copeland said, “Serving as GOG-F President has been one of the greatest privileges of my career, and I am delighted that the next President will be Dr Thomas Herzog. Over the past few years, he has worked tirelessly on many fronts to advance our mission. He has demonstrated his vision and passion for clinical trials to transform the standard of care for women with gynecological cancers. After successful trials, he also showed a strong commitment to “getting the word out.” by organizing and participating in informative educational programs. As Past President, I pledge my full support to Tom in leading GOG-F to continued success.
When Dr. Herzog takes office, he will be responsible for GOG-F Inc., which includes the GOG Foundation’s corporate membership in the NRG Oncology and GOG-P program. The GOG-F, formerly known as the Gynecologic Oncology Group, in conjunction with the NSABP and RTOG, formed a new 501(C)(3), in 2013, NRG Oncology Foundation, Inc. In addition to the responsibilities of the NRG, Dr. Herzog will also oversee the GOG Partners program, also founded in 2013.
About the GOG Foundation, Inc. (www.gog.org)
The GOG Foundation, Inc. is a non-profit organization whose purpose is to promote excellence in the quality and integrity of clinical and translational scientific research in the field of gynecological malignancies. The GOG Foundation is committed to maintaining the highest standards in the development, execution, analysis and distribution of clinical trial results. The GOG Foundation is the only clinical trial group in the United States that focuses its research on patients with pelvic malignancies, such as cancer of the ovary (including surface peritoneal malignancies), uterine (including endometrium, soft tissue sarcoma and gestational trophoblastic neoplasia), cervix and vulva. The GOG Foundation is multidisciplinary in its approach to clinical trials and includes gynecological oncologists, medical oncologists, pathologists, radiation oncologists, oncology nurses, biostatisticians (including those with expertise in bioinformatics), basic scientists , quality of life experts, data managers, and administrative staff.
About NRG Oncology (www.nrgoncology.org)
NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of cancer patients. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that incorporates research from the legacy of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the former Gynecologic Oncology Group, now The GOG Foundation, Inc. (GOG). The research network seeks to conduct clinical trials with an emphasis on sex-specific malignancies, including gynecological, breast and prostate cancers, and localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization includes multidisciplinary researchers, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists and statisticians, and encompasses more than 1,300 research sites located worldwide, with a predominance in the United States and Canada. NRG Oncology is supported primarily by grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.
About GOG Partners
Industry-backed, GOG Partners is structured to work directly with pharmaceutical organizations and conduct clinical trials outside of the National Cancer Institute (NCI) framework. GOG Partners share the same mission of the GOG Foundation dedicated to transforming care in gynecological oncology. By providing an alternate venue for patient recruitment and site infrastructure support, GOG Partners has helped provide additional trials and opportunities for patients outside of the National Gynecology Clinical Trials Network.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.